Management of febrile urinary tract infection among spinal cord injured patients by unknown
RESEARCH ARTICLE Open Access
Management of febrile urinary tract
infection among spinal cord injured
patients
Aurélien Dinh1*, Adnène Toumi2, Constance Blanc1, Alexis Descatha1, Frédérique Bouchand3, Jérôme Salomon1,
Thomas Hanslik4, Benjamin Bernuz5, Pierre Denys5 and Louis Bernard6
Abstract
Background: Urinary tract infection (UTI) among patients with neurogenic bladder is a major problem but its
management is not well known. We studied the relationship between antibiotic regimen use and the cure rate of
those infections among 112 patients with neurogenic bladder.
Methods: We studied a retrospective cohort of febrile UTI among patients with neurogenic bladder. Drug selection
was left to the discretion of the treating physicians, in accordance with current guidelines. Patients were divided
into 3 groups according to antibiotic treatment duration (<10 days, between 10 and 15 days, and >15 days). We
analysed clinical and microbiogical cure rate one month after the end of antibiotic treatment.
Results: The three groups of patients were similar, especially in terms of drug treatment (equal distribution). The
cure rates were not significantly different (71.4 %, 54.2 %, and 57.1 %, respectively; p = 0.34). Moreover, there was no
difference in cure rate between mono and dual therapy (44 % for monotherapy vs. 40 % for dual therapy; p = 0.71).
Conclusion: This descriptive study supports the efficacy of antimicrobial treatment duration of less than 10 days
and the use of monotherapy to treat febrile UTI among patients with neurogenic bladder. A randomized control
trial is required to confirm these data.
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Background
Urinary tract infection (UTI) is one of the most com-
mon infectious diseases, especially among patients with
neurogenic bladder. These patients are more likely to
develop UTI than the general population [1–3]. Fever
during UTI suggests the presence of tissue inflamma-
tion, which could lead to severe sepsis [4]. Despite void-
ing practices maintaining low pressure bladder such as
intermittent catheterizations, febrile UTI among patients
with neurogenic bladder is still the primary cause of
morbidity and hospitalization [1, 5].
Guidelines about the duration of antibiotic treatment
for acute pyelonephritis are usually 7 to 14 days, and
21 days for complicated forms such as in patients with
neurogenic bladder [6]. Shorter antibiotic treatments are
considered helpful to reduce the development of antibiotic
resistance and reduce toxicity. No recommendations
about the duration of antibiotic treatment currently exist
for patients with neurogenic bladder.
We aimed to describe cure rates of febrile UTI, ac-
cording to different antibiotic treatment regimens, in a
cohort of patients with neurogenic bladder who were
followed in a specialist rehabilitation center.
Methods
This retrospective study was conducted from January
the 1st 2008 to December the 31st 2013 in a University
Hospital, with acute care facilities (255 beds, including
43 beds of adult intensive care) and a 108-bed rehabilita-
tion unit (with 40 beds dedicated to spinal cord injured
patients). There are about 8400 admissions per year for
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complete hospitalization. This study was approved by
the Saint-Germain-en-Laye ethical (CPP IDF XI) review
committee (N° 06070).
Patients
Hospitalized patients with neurogenic bladder diagnosed
with febrile UTI were enrolled in this study if they ful-
filled the 3 following criteria: 1) fever > 38 °C; 2) at least
one of the following clinical signs lasting less than five
days: pyuria, dysuria, frequent urination, urgent urination,
perineal or flank pain, clinical autonomic dysreflexia
(which is associated with throbbing headaches, profuse
sweating, nasal stuffiness, flushing of the skin above the
level of the lesion, slow heart rate); 3) a positive urine
culture defined as a urine bacterial count ≥105 colony-
forming units (CFU)/mL [7] ; 4) management as a UTI
by the physician on charge, with relevant and appropriate
antimicrobial prescription according to usual guidelines,
and absence of other possible diagnosis.
Methods
Susceptibility to antibiotics was determined using disk
diffusion according to the CA-SFM recommendations
[8]. For patients with an indwelling urinary catheter, the
urine sample was collected from the port of the catheter.
The following information about antibiotic treatment
was collected from medical charts using a standard
questionnaire:
– Drug treatment
– Duration: patients were divided into three groups
according to the duration of antibiotic treatment.
Group 1, less than 10 days of treatment; group 2,
between 10 and 15 days of treatment; and group 3,
more than 15 days of treatment. Duration was the
time during which the patient received
microbiologically appropriate antibiotic treatment
considering the final result of his urine culture.
– Mono or dual therapy: dual therapy was defined as
the simultaneous use of two antibiotics effective
against the particular pathogens involved, for at least
one day during the course of treatment. Only
antibiotics that have shown to be effective against
febrile UTI according to international guidelines and
with proven efficacy based on susceptibility testing
were considered for use in dual therapy and
treatment duration [6].
The following information was obtained for each case
of febrile UTI at diagnosis: clinical data (including type
of neurological deficit and voiding practice), bacterio-
logical data, leukocyte count, C-reactive protein level.
End-point
The cure rate was determined one month after the end
of antibiotic treatment from a medical interview [9, 10].
Cure was defined as the complete resolution of symp-
toms and clinical signs related to UTI without the need
for additional or alternative antibiotic therapy. A urine
culture was performed at the same time.
Failure was defined as the persistence or progression of
symptoms or signs of UTI, or death related to UTI. Pa-
tients who could not be evaluated either died due to a
condition unrelated to UTI, were lost to follow up, or
required another antibiotic treatment during follow up
for a concomitant infection outside the urinary tract,
were included in the study but not in the outcome ana-
lysis. These patients were considered as undetermined.
Statistical analysis
Data analyses were carried out with the SAS 9.3 software
(SAS Institute Inc., Cary, NC, USA). Univariate analyses
were carried out with chi2 and Fisher exact tests, including
all variables known to be associated with UTI (i.e. statis-
tical or clinically significant): sex, age, type of neurological
deficit, type of voiding management, positive blood culture
[1, 11, 12].
Statistical significance was defined as p < 0.05.
Results
There were 112 cases of febrile UTI among 94 patients
with neurogenic bladder. The baseline characteristics of
the 94 patients and the outcome of the 112 episodes are
listed in Table 1. Of the 94 patients, 83 had a unique
episode.
The population was mostly male (80/112) with young
adults (mean age: 38.4 years old ± 11.7) and paraplegic
patients (n = 65; 58 %). The most frequent bladder voiding
method was intermittent catheterization (n = 57; 51 %).
During UTI, patients had a mean temperature of 38.8 °C
(±0.6 °C) and mean C reactive protein level was 121 mg/L
(±84); 15 % (n = 17) of patients had positive blood culture.
The main bacteria involved were E. coli (n = 55; 49 %),
Pseudomonas aeruginosa (n = 19; 13.5 %) and Entero-
coccus spp. (n = 19; 13.5 %). Twenty nine (26 %) UTIs
were polymicrobial, with four involving 3 microorganisms
and 25 involving 2. Mean treatment duration was 18.1 days
and dual therapy was prescribed in 62 % (n = 69) of cases.
Global cure rate was 60 % (n = 67) and failure 27.5 %
(n = 31). Fourteen patients (12.5 %) could not be evaluated.
Eleven patients had recurrent febrile UTI: seven pa-
tients had two episodes of UTI, three patients had three,
and one patient suffered six. Of these patients, three
(27 %) had urinary diversion and three others (27 %)
used reflex voiding.
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Table 1 Characteristics and outcome of 112 febrile urinary tract infection occurring among patients with neurogenic bladder
depending on treatment duration
Treatment duration (days) <10 d 10-15 d >15 d Total P value
Number of febrile UTIa 28 35 49 112
Patient characteristics
Sex (women/men) 12/16 11/24 9/40 32/80 0.2453
Age: mean year (SD) 49.6 (20.1) 46.5 (24.7) 31 (19.7) 38.4 (11.7) 0.1443
Fever: mean °C (SD) 38.6 (0.33) 38.9 (0.76) 39.07 (0.78) 38.8 (0.6) 0.5469
Neurological deficit N (%)
Paraplegia 18 (64) 20 (57) 27 (55) 65 (58) 0.2604
Tetraplegia 5 (18) 2 (6) 13 (27) 20 (18) 0.5205
Multiple sclerosis 4 (14) 6 (17) 6 (12) 16(14) 0.9299
Brain injury 1 (4) 7 (20) 3 (6) 11(10) 0.1042
Voiding management N (%)
Intermittent cathererization 14 (50) 13 (37.1) 30 (62) 57 (51) 0.4564
Indwelling catheter 2 (7) 4 (11) 6 (12) 12 (10) 0.9899
Reflex voiding 7 (25) 8 (23) 7 (14) 22 (19) 0.8349
Urinary diversion 2 (7) 6 (17) 3 (6) 11 (10)
Others 3 (11) 4 (11) 3 (6) 10 (10)
Biological variables
Leukocyte count: median/L (SD) 12. 9 (5.5) 13 (6.9) 12 (5.7) 12.6 (6) 0.4426
CRP mean mg/l (SD) 140 (84) 139 (89) 122(90) 121 (84) 0.9953
Positive blood culture N (%) 3 (10) 5 (14) 9 (18) 17 (15) 0.5246
Microorganism sample N (%)
E coli 17 (53) 16 (37.2) 22 (33) 55 (49)
Pseudomonas aeruginosa 6 (18.7) 6 (13.9) 7 (10.6) 19 (13.5)
Enterococcus 4 (12.5) 7 (16.2) 8 (12) 19 (13.5)
Klebsiella 2 (6.25) 4 (9.3) 8 (12) 14 (10)
Proteus 1 (3.12) 3 (7) 4 (6) 8(5.6)
Others 2 (6.43) 7 (16.4) 17 (26.4)) 26 (18.4)
Antibiotic treatment
Mean treatment duration (SD) 7.9 (2.3) 13.4 (1.9) 27.3 (9.8) 18.1 (10.7) 0.0250
Mean parenteral treatment duration (median, SD) 8 (8, ±2.2) 6.8 (5, ±5.33) 11.2 (7, ±10.6) 8.2 (6, ±8.3)
Dual therapy N (%) 17 (61) 18 (52) 34 (70) 69 (62) 0.9669
Antibiotic treatment N (%)
Third generation cephalosporin 16 (33) 19 (26.3) 32 (32) 67 (30.6)
Aminoglycosides 12 (25) 18 (25) 21 (21) 51 (23.2)
Fluoroquinolones 6 (12.5) 14 (19.4) 16 (16) 36 (16.4)
Penicillin 9 (18.8) 12 (16.7) 14 (14) 35 (16)
Carbapenem 4 (8.3) 5 (6.9) 11 (11) 20 (9.1)
Colimycin 1 (2) 2 (2.8) 2 (2) 5 (2.3)
Cotrimoxazole 0 0 3 (3) 3 (1.4)
Fosfomycin 0 2 (2.8) 0 2 (1)
Outcome (1 month)
Cure N (%) 20 (71.4) 19 (54.2) 28 (57.1) 67 (60.0) 0.3979
Failure N (%) including: 6 (21.6) 10 (28.5) 15 (30.8) 31 (27.5)
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There was no difference between the variables mea-
sured in these patients (sex, age, type of neurogenic def-
icit, voiding practice) and those measured in patients
without recurrent UTI who were included in the study.
There was no difference from the general population
of the study, except for numerous patients with non-
stabilized bladder.
The mean duration of antibiotic treatment for these
patients was 17 days (1–60).
All kidney examinations and/or abdominal CT scans
were normal: no abscess or obstruction. No surgery or
derivation had been performed.
The most commonly prescribed antibiotics, considering
only appropriate antimicrobial treatment, were third gen-
eration cephalosporins (n = 67), aminoglycosides (n = 51),
and fluoroquinolones (n = 36).
Considering the three groups of patients, there was no
statistically significant difference in sex ratio, type of
neurological deficit, positive blood culture, prescribed
antibiotics, and mono or dual therapy. There was no sig-
nificant difference in the cure rate of the three groups
(p = 0.3979) (assessed by either a Chi2 or an exact test).
Considering follow up urine culture at day 30, there was
no significant difference in bacteriuria rate of the three
groups (p = 0.635).
Moreover, there was no difference in cure rate be-
tween mono and dual therapy (44 % for monotherapy
versus 40 % for dual therapy, p = 0.071), regardless of the
treatment duration.
Discussion
Our study compared the outcomes of febrile UTI among
patients with neurogenic bladder according to different
appropriate antimicrobial durations, and mono or dual
therapy. We did not find any difference between treat-
ment durations of less than 10 days, 10 to 15 days or
more than 15 days. Moreover there was no difference
between mono and dual antimicrobial therapies.
There are no well-established guidelines for the opti-
mal antibiotic treatment of febrile UTI in patients with
neurogenic bladder. Physicians tend to prescribe antibiotics
for a long duration, often with dual therapy, depending on
voiding difficulties and on the risk of vesico ureteric reflux.
However, long term treatment is considered to be associ-
ated with a high risk of toxicity; therefore, this practice may
be deleterious and could probably lead to the emergence of
multidrug resistant bacteria in patients already frequently
exposed to antibiotics [13, 14].
The global low cure rate compared to the rate in usual
UTI is often associated with neurogenic bladder [1]. The
higher cure rate for group 1, which is the shorter anti-
biotic treatment group, is possibly linked to the absence
of randomization. The fast resolution of symptoms of
UTI could have led to shorter antimicrobial treatment.
Considering microbiological data as a cure criterion
among a population with neurogenic bladder is under
debate because of the frequent asymptomatic bacteriuria
in this population [14]. The overall rate of negative urine
culture was not statistically different in the three groups.
Our study has several limitations. First it is a non-
randomized trial and treatment duration was decided on
subjective criteria and depended on the physician in
charge and the clinical presentation of the UTI. Several
patients (n = 3) were lost to follow up, treated with anti-
biotics for another reason (n = 5), or died for another
reason (n = 6), which is a potential bias. Patients had
various neurological deficits and voiding practices,
leading to a heterogeneous population, and treatment
could have different outcome depending on these bladder
characteristics. Also, we considered different microorgan-
isms and antimicrobial treatments. Moreover, changes in
antibiotic policy over the 6 years could also have affected
the analysis.
Although the statistical strength of this study is limited,
it nonetheless contains one of the largest cohorts pub-
lished to date. These patients were treated at a specialist
center.
The treatment duration and the use of mono or dual
therapy were decided by the physician because this was
a non-interventional trial. However, there was no difference
Table 1 Characteristics and outcome of 112 febrile urinary tract infection occurring among patients with neurogenic bladder
depending on treatment duration (Continued)
Persistence of symptoms 5 (17.8) 9 (25.7) 12 (24.4) 26 (23.2)
Death related to UTI 1 (3.5) 1 (3) 3 (6.1) 5 (4.4)
Patients who could not be evaluated N (%)b 2 (7.1) 6 (17.1) 6 (12.2) 14 (12.5)
Requiring another antibiotic treatment for concomitant infection 0 1 4 5
Lost to follow up 1 1 1 3
Death unrelated to UTI 1 4 1 6
Negative urine culture (D30) N (%) 17 (60.7) 15 (42.8) 21 (42.8) 53 (47.3) 0.635
aUTI = urinary tract infection
bPatients who could not be evaluated: included death unrelated to UTI (n = 6); patients lost to follow-up (n = 3), and patients requiring another antibiotic treatment
for a concomitant infection (n = 5)
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in outcome between the three groups of treatment
duration.
Our definition of cure which considers only the ab-
sence of clinical symptoms is based on the guideline not
to treat asymptomatic bacteriuria in patients with neuro-
genic bladder [2, 3]. This situation is common in this
population and the diagnosis of infection is mainly sup-
ported by clinical symptoms. Furthermore, the threshold
of bacteriuria to diagnose infection in this population is
matter of discussion.
Nevertheless, considering microbiological results of
urine culture, we found no difference in the three groups
of treatment duration (p = 0.635).
Treatment duration is a subject of wide debate. Studies
suggest that a short length (5 days) of antibiotic treatment
should be encouraged for uncomplicated pyelonephritis
[15, 16]. Generally shortening antibiotic treatment dur-
ation is a leading goal in public health. It is considered as
a tool to fight against bacterial resistance and has several
other advantages such as the reduction of side effects and
cost. Even if we have not measured these components in
our study, we are convinced that short antibiotic treat-
ment duration tend towards these advantages.
The only clinical trial to date about UTI in patients
with neurogenic bladder revealed that 14 days of cipro-
floxacin treatment is associated with a higher cure rate
than only three days of this treatment [5]. Three days
may not be enough; however, in our study, we find no
difference in the outcome of the three treatment groups.
These findings support the trend to use short duration
antibiotic treatments of less than 14 days.
The use of dual therapy involving aminoglycosides to
treat UTI is controversial [17, 18]. Recommendations
usually suggest that aminoglycosides should be used only
in cases of severe sepsis or for particular bacteria such
as Pseudomonas aeruginosa or AmpC-producing Entero-
bacteriaceae [6]. Most of these microorganisms are rare
in cases of UTI in the general population but more fre-
quent in patients with neurogenic bladder. Furthermore
the high frequency of polymicrobial infection can pro-
mote the use of a dual therapy.
Aminoglycosides are potentially highly toxic mole-
cules, and their use should be limited to protect renal
function. We suggest that the use of aminoglycosides be
avoided for UTI among patients with neurogenic bladder,
except for cases of AmpC-producing Enterobacteriaceae
and severe sepsis.
Conclusions
As our study found no difference of outcome between
long and short antibiotic treatment duration either with
mono or dual therapy, this suggests that a long treatment
duration and dual antibiotic therapy could be unnecessary
for the management of febrile UTI in patients with neuro-
genic bladder.
According to our data, the management of febrile UTI
among patients with neurogenic bladder does not seem
to require longer treatment duration than for patients
without disability. In our center we recommend an ap-
propriate antimicrobial treatment duration of 8 days for
patients with neurogenic bladder.
These promising results should be confirmed by add-
itional data and randomized trials.
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